Correlation Between Immune Related Adverse Events With Clinical Efficacy In Solid Tumors Treated With Immune Checkpoint Inhibitors

With the development of precision medicine,many malignant tumors have entered the era of immunotherapy.The checkpoint inhibitors for programmed death receptor-1(PD-1)and its ligand-1(PD-L1)and cytotoxic T lymphocyte antigen-4(CTLA-4)have made a breakthrough in the treatment of many solid tumors.With the increasing clinical application of immune checkpoint inhibitors in a variety of solid tumors,more and more immune-related adverse events have been observed by clinicians.Immune related adverse events(ir AEs)are autoimmune toxic effects related to immune checkpoint inhibitors(ICIs).Some studies have shown that immune-related adverse events are related to clinical benefits of immune checkpoint inhibitors,and their occurrence and development are related to response duration of treatment and disease prognosis.In this paper,i present a case of relapsed and progressive malignant melanoma of the back in our department,which was treated with pembrolizumab,an immune checkpoint inhibitors,to achieve partial response of the disease,and sustained response to the therapeutic effect after discontinuation of the drug.Through the accompanying phenomenon of immune related adverse events and treatment response in this patient,we further discuss the relationship between immune related adverse events and therapeutic efficacy of immune checkpoint inhibitors in solid tumors.